Search Results

The BD Directigen™ EZ Flu A+B test is a rapid chromatographic immunoassay for the direct and qualitative detection of influenza A and B viral antigens from nasopharyngeal washes/aspirates and throat swabs of symptomatic patients. The BD Directigen™ EZ Flu A+B test is a differentiated test, and therefore influenza A viral antigens can be distinguished from influenza B viral antigens from a single processed sample using a single device. The test is to be used as an aid in the diagnosis of influenza A and B viral infections. All negative test results should be confirmed by cell culture.

The BD Directigen™ EZ Flu A+B test is a chromatographic assay to qualitatively detect influenza A and B viral antigens in samples processed from respiratory specimens. When specimens are processed and added to the test device, influenza A and/or B viral antigens bind to anti-influenza antibodies conjugated to visualizing particles in the corresponding A and B test strips. The antigen-conjugate complex migrates across the test strip to the reaction area and is captured by the line of antibody on the membrane. A positive result is visualized as a reddish purple line at the Test "T" position in the Flu A or Flu B read window in combination with a reddish purple line at the Control "C".

Here's an analysis of the acceptance criteria and study details for the BD Directigen™ EZ Flu A+B, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The submission does not explicitly state pre-defined acceptance criteria in terms of specific sensitivity and specificity thresholds. Instead, it demonstrates "substantial equivalence" to predicate devices and viral cell culture. The reported performance values are:

2. Sample Size Used for the Test Set and Data Provenance

The text states: "Performance characteristics of the BD Directigen EZ Flu A+B test were determined by calculating sensitivity and specificity of the BD Directigen EZ Flu A+B test compared to culture for prospectively collected nasopharyngeal wash/aspirate and throat specimens in both an adult and pediatric population."

• Test Set Sample Size: The exact numerical sample size for the clinical study (test set) is not explicitly provided in the document.
• Data Provenance: The data was prospectively collected from a multi-center study that was "geographically diverse." The country of origin is not specified, but given the submission to the FDA, it is highly likely to be the USA. The specimens were from "symptomatic patients."

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

The ground truth for the clinical study was established by viral cell culture. This is a laboratory method, not reliant on human expert interpretation in the same way an imaging study would be. Therefore, the concept of "number of experts" and their "qualifications" doesn't directly apply here for establishing the primary ground truth.

4. Adjudication Method for the Test Set

As the primary ground truth was established by viral cell culture, there was no human adjudication method described for the test set interpretation itself. The BD Directigen™ EZ Flu A+B test results were compared against the cell culture results.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance

• No MRMC study was done. This device is a rapid diagnostic test (an immunoassay) for direct antigen detection, not an AI-powered diagnostic tool intended for interpretation by human readers. Therefore, the concept of human reader improvement with AI assistance is not applicable.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

• Yes, a standalone study was done. The clinical performance reported (sensitivity and specificity) is for the BD Directigen™ EZ Flu A+B test operating as a standalone diagnostic device, comparing its results directly to cell culture. There is no human-in-the-loop element mentioned for the primary output of this device.

7. The Type of Ground Truth Used

• The primary ground truth used for the clinical performance evaluation was viral cell culture.
• The device was also compared to Direct Fluorescent Antibody (DFA) tests, the BD Directigen™ Flu A+B test, and the Remel Xpect™ FLU A/B test in a "device comparison" context, suggesting these served as secondary or comparative ground truths/references.

8. The Sample Size for the Training Set

• The document does not provide any information regarding a "training set" or its sample size. This is typical for traditional (non-AI/machine learning) diagnostic devices. The device's performance is established through analytical and clinical validation, not by training a model on a dataset.

9. How the Ground Truth for the Training Set Was Established

• As there is no mention of a training set, the method for establishing its ground truth is not applicable and not provided.

Ask a specific question about this device